Federal Register Notice: FDA will hold a public meeting 9/22 on Patient-Focused Drug Development for Hemophilia A, Hemophilia B, von Willebrand Disease, and other heritable bleeding disorders such as other factor deficiencies (including I, V, VII, X, XI) and platelet disorders. The public meeting is intended to provide FDA with patients’ perspectives on the impact on daily life of such bleeding disorders and to gain patients’ perspectives on the available therapies for these disorders. The meeting will be held from 9 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503 B and C), Silver Spring, MD. Contact Henry Allen, (240) 402-8001. To view this notice, click here.